| Year |
Citation |
Score |
| 2024 |
Mehta A, Popplewell L, Collins GP, Smith SM, Flinn IW, Bartlett NL, Ghosh N, Hacohen-Kleiman G, Huo Y, Su-Feher L, Renard C, Advani RH, Roschewski M. Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Phase 1/2 Trial 3-Year Follow-up. Blood Advances. PMID 39213421 DOI: 10.1182/bloodadvances.2024013277 |
0.334 |
|
| 2024 |
Danilov AV, Flinn IW, Davids MS, Gregory B, Bentur O, Sidransky D, Brown JR. The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival. Haematologica. PMID 38813715 DOI: 10.3324/haematol.2024.285043 |
0.306 |
|
| 2024 |
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, et al. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302329. PMID 38547425 DOI: 10.1200/JCO.23.02329 |
0.388 |
|
| 2023 |
Matasar M, Bartlett NL, Shadman M, Budde LE, Flinn I, Gregory GP, Kim WS, Hess G, El-Sharkawi D, Diefenbach CS, Huang H, To I, Parreira J, Wu M, Kwan A, et al. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma, Myeloma & Leukemia. PMID 38195322 DOI: 10.1016/j.clml.2023.12.005 |
0.316 |
|
| 2023 |
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, et al. First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. Cancer Discovery. PMID 37930156 DOI: 10.1158/2159-8290.CD-23-0670 |
0.413 |
|
| 2023 |
Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CYY, Matasar MJ, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn IW, Johnston A, Bosch F, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. PMID 37067952 DOI: 10.1182/bloodadvances.2022009260 |
0.37 |
|
| 2023 |
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff PJ, Flinn IW, Farooq U, et al. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood. PMID 36821768 DOI: 10.1182/blood.2022018893 |
0.38 |
|
| 2022 |
Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, et al. Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Ejhaem. 3: 139-153. PMID 35846221 DOI: 10.1002/jha2.375 |
0.393 |
|
| 2022 |
Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, et al. Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. Ejhaem. 3: 394-405. PMID 35846031 DOI: 10.1002/jha2.394 |
0.393 |
|
| 2022 |
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, ... ... Flinn IW, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. The Lancet. Oncology. PMID 35810754 DOI: 10.1016/S1470-2045(22)00293-5 |
0.335 |
|
| 2022 |
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102370. PMID 35658525 DOI: 10.1200/JCO.21.02370 |
0.311 |
|
| 2022 |
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. The New England Journal of Medicine. PMID 35657079 DOI: 10.1056/NEJMoa2201817 |
0.332 |
|
| 2022 |
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, ... Flinn IW, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial. Haematologica. PMID 35021599 DOI: 10.3324/haematol.2021.279012 |
0.325 |
|
| 2021 |
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100931. PMID 34914545 DOI: 10.1200/JCO.21.00931 |
0.331 |
|
| 2021 |
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. The New England Journal of Medicine. PMID 34904798 DOI: 10.1056/NEJMoa2116596 |
0.304 |
|
| 2021 |
Davids MS, O'Connor OA, Jurczak W, Samaniego F, Fenske TS, Zinzani PL, Patel MR, Ghosh N, Cheson BD, Derenzini E, Brander DM, Reeves JA, Knopinska-Posluszny W, Allan JN, Phillips T, ... ... Flinn IW, et al. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies. Blood Advances. PMID 34547767 DOI: 10.1182/bloodadvances.2021005132 |
0.397 |
|
| 2021 |
Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, ... Flinn I, et al. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. PMID 34172893 DOI: 10.1038/s41375-021-01328-9 |
0.332 |
|
| 2021 |
Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, Salles GA, Trněný M, de Vos S, Mir F, Samineni D, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 137: 600-609. PMID 33538797 DOI: 10.1182/blood.2020006578 |
0.356 |
|
| 2021 |
Berdeja JG, Gregory TK, Faber EA, Hart LL, Mace JR, Arrowsmith ER, Flinn IW, Matous JV. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort. American Journal of Hematology. PMID 33421178 DOI: 10.1002/ajh.26088 |
0.386 |
|
| 2020 |
Wagner-Johnston ND, Schuster SJ, deVos S, Salles G, Jurczak WJ, Flowers CR, Viardot A, Flinn IW, Martin P, Xing G, Rajakumaraswamy N, Gopal AK. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leukemia & Lymphoma. 1-11. PMID 33300385 DOI: 10.1080/10428194.2020.1855344 |
0.35 |
|
| 2020 |
Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, Salles GA, Trneny M, de Vos S, Mir F, Samineni D, et al. A phase II study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. PMID 32959049 DOI: 10.1182/blood.2020006578 |
0.354 |
|
| 2020 |
Ansell SM, Flinn I, Taylor MH, Sikic BI, Brody J, Nemunaitis J, Feldman A, Hawthorne TR, Rawls T, Keler T, Yellin MJ. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Advances. 4: 1917-1926. PMID 32380537 DOI: 10.1182/Bloodadvances.2019001079 |
0.349 |
|
| 2020 |
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. The New England Journal of Medicine. 382: 1331-1342. PMID 32242358 DOI: 10.1056/Nejmoa1914347 |
0.44 |
|
| 2020 |
Fowler NH, Nastoupil L, De Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Davis RE, Neelapu SS, Eckert K, Ping J, Co M, et al. The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. British Journal of Haematology. PMID 32180219 DOI: 10.1111/bjh.16424 |
0.331 |
|
| 2019 |
Flinn IW, Cherry MA, Maris MB, Matous JV, Berdeja JG, Patel M. Combination Trial of Duvelisib (IPI-145) with Rituximab or Bendamustine/Rituximab in Patients with Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. American Journal of Hematology. PMID 31490009 DOI: 10.1002/ajh.25634 |
0.391 |
|
| 2019 |
Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, et al. A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica. PMID 31413095 DOI: 10.3324/haematol.2019.223743 |
0.312 |
|
| 2019 |
Flinn IW, Erter J, Daniel DB, Mace JR, Berdeja JG. Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy. The Oncologist. PMID 31073022 DOI: 10.1634/theoncologist.2019-0286 |
0.342 |
|
| 2019 |
Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, et al. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801460. PMID 30995176 DOI: 10.1200/Jco.18.01460 |
0.365 |
|
| 2019 |
Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). The Lancet. Haematology. PMID 30935953 DOI: 10.1016/S2352-3026(19)30026-2 |
0.331 |
|
| 2019 |
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900010. PMID 30897038 DOI: 10.1200/JCO.19.00010 |
0.338 |
|
| 2019 |
Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800915. PMID 30742566 DOI: 10.1200/Jco.18.00915 |
0.342 |
|
| 2019 |
Bachanova V, Cohen J, Akard L, Jaglowski S, Sachs J, Ranger A, Harris P, McGinness K, Motz G, Flinn I. Abstract A003: Safety and preliminary efficacy of ACTR707, autologous T lymphocytes expressing an antibody-coupled T-cell receptor, in combination with rituximab in subjects with relapsed or refractory CD20-positive B-cell lymphoma Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A003 |
0.448 |
|
| 2019 |
Bartlett NL, Sehn LH, Assouline S, Bosch F, Diefenbach CM, Flinn I, Hong JY, Kim WS, Matasar M, Nastoupil L, Schuster SJ, Shadman M, Yoon S, Bender B, Chu W, et al. Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Clinical Lymphoma Myeloma and Leukemia. 19: S247. DOI: 10.1016/J.Clml.2019.07.151 |
0.347 |
|
| 2018 |
Coutre SE, Flinn IW, de Vos S, Barrientos JC, Schreeder MT, Wagner-Johnson ND, Sharman JP, Boyd TE, Fowler N, Dreiling L, Kim Y, Mitra S, Rai K, Leonard JP, Furman RR. Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. Hemasphere. 2: e39. PMID 31723767 DOI: 10.1097/HS9.0000000000000039 |
0.39 |
|
| 2018 |
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. The Lancet. Oncology. PMID 30518502 DOI: 10.1016/S1470-2045(18)30864-7 |
0.356 |
|
| 2018 |
Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, et al. Molecular remission and response patterns in patients with mutant- acute myeloid leukemia treated with enasidenib. Blood. PMID 30510081 DOI: 10.1182/Blood-2018-08-869008 |
0.37 |
|
| 2018 |
Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine. 379: 1711-1721. PMID 30380386 DOI: 10.1056/Nejmoa1807315 |
0.365 |
|
| 2018 |
Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, et al. The phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL. Blood. PMID 30287523 DOI: 10.1182/blood-2018-05-850461 |
0.399 |
|
| 2018 |
Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, et al. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leukemia & Lymphoma. 1-10. PMID 30277102 DOI: 10.1080/10428194.2018.1515940 |
0.372 |
|
| 2018 |
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. The New England Journal of Medicine. 379: 934-947. PMID 30184451 DOI: 10.1056/Nejmoa1805104 |
0.496 |
|
| 2018 |
Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, ... ... Flinn IW, et al. Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies. American Journal of Hematology. PMID 30129285 DOI: 10.1002/ajh.25259 |
0.388 |
|
| 2018 |
O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, ... ... Flinn I, et al. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study. American Journal of Hematology. PMID 30094870 DOI: 10.1002/Ajh.25243 |
0.4 |
|
| 2018 |
Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B. Duvelisib, an Oral Dual PI3K-δ, γ Inhibitor, Shows Clinical Activity in Indolent Non-Hodgkin Lymphoma in a Phase 1 Study. American Journal of Hematology. PMID 30033575 DOI: 10.1002/ajh.25228 |
0.368 |
|
| 2018 |
Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, Augustson B, Marlton P, Renee Commerford S, Okrah K, Liu L, Murray E, Penuel E, Ward AF, Flinn IW. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 9: 13023-13035. PMID 29560128 DOI: 10.18632/oncotarget.24310 |
0.362 |
|
| 2018 |
Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Investigational New Drugs. PMID 29453628 DOI: 10.1007/s10637-018-0570-4 |
0.397 |
|
| 2017 |
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England Journal of Medicine. PMID 29226797 DOI: 10.1056/Nejmoa1707447 |
0.41 |
|
| 2017 |
Flinn IW, Thompson DS, Boccia RV, Miletello G, Lipman A, Flora D, Cuevas D, Papish SW, Berdeja JG. Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. British Journal of Haematology. PMID 29193021 DOI: 10.1111/bjh.15044 |
0.37 |
|
| 2017 |
Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. PMID 29191916 DOI: 10.1182/blood-2017-05-786566 |
0.353 |
|
| 2017 |
Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, et al. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017732784. PMID 28862883 DOI: 10.1200/JCO.2017.73.2784 |
0.326 |
|
| 2017 |
Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, Parker J, Hafeez A, Tuck D, Younes A. CUDC-907 in relapsed/refractory diffuse Large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial. Haematologica. PMID 28860342 DOI: 10.3324/haematol.2017.172882 |
0.372 |
|
| 2017 |
Donnellan W, Berdeja JG, Shipley D, Arrowsmith ER, Wright D, Lunin S, Brown R, Essell JH, Flinn IW. A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia. The Oncologist. PMID 28687625 DOI: 10.1634/Theoncologist.2017-0236 |
0.414 |
|
| 2017 |
Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, et al. Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia. Blood. PMID 28588020 DOI: 10.1182/Blood-2017-04-779405 |
0.379 |
|
| 2017 |
Kuruvilla J, Savona M, Baz R, Mau-Sorensen M, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin's lymphoma. Blood. PMID 28468797 DOI: 10.1182/Blood-2016-11-750174 |
0.391 |
|
| 2017 |
Tees MT, Flinn IW. Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care? Current Treatment Options in Oncology. 18: 16. PMID 28286923 DOI: 10.1007/s11864-017-0459-z |
0.326 |
|
| 2017 |
Coutré SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, et al. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28073846 DOI: 10.1158/1078-0432.CCR-16-1431 |
0.349 |
|
| 2017 |
Sharman JP, Brander DM, Mato AR, Kambhampati S, Burke JM, Lansigan F, Schreeder MT, Lunin SD, Ghosh N, Zweibach A, Shtivelband M, Travis PM, Chandler JC, Kolibaba KS, Sportelli P, ... ... Flinn I, et al. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study. Journal of Clinical Oncology. 35: 7504-7504. DOI: 10.1200/Jco.2017.35.15_Suppl.7504 |
0.44 |
|
| 2017 |
Flinn I, Jagt Rvd, Chang JE, Wood P, Hawkins TE, MacDonald D, Trotman J, Simpson D, Kolibaba KS, Issa S, Hallman DM, Chen L, Burke JM. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study. Journal of Clinical Oncology. 35: 7500-7500. DOI: 10.1200/Jco.2017.35.15_Suppl.7500 |
0.353 |
|
| 2017 |
Tam CS, Quach H, Nicol A, Badoux X, Rose H, Prince HM, Leahy MF, Eek R, Wickham N, Patil SS, Huang J, Zhang X, Wang L, Hedrick E, Novotny W, ... Flinn IW, et al. BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma Blood. 130: 1745-1745. DOI: 10.1182/Blood.V130.Suppl_1.1745.1745 |
0.376 |
|
| 2016 |
de Vos S, Wagner-Johnston ND, Coutre SE, Flinn IW, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Kim Y, Godfrey WR, Leonard JP. Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma. Blood Advances. 1: 122-131. PMID 29296805 DOI: 10.1182/bloodadvances.2016000976 |
0.41 |
|
| 2016 |
Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. PMID 27979923 DOI: 10.3324/Haematol.2016.151738 |
0.35 |
|
| 2016 |
Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, et al. Real-world clinical experience in the Connect(®) chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. British Journal of Haematology. PMID 27861736 DOI: 10.1111/bjh.14332 |
0.305 |
|
| 2016 |
Flinn IW, Ruppert AS, Harwin W, Waterhouse D, Papish S, Jones JA, Hainsworth J, Byrd JC. A Phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia (CLL). American Journal of Hematology. PMID 27387131 DOI: 10.1002/ajh.24468 |
0.405 |
|
| 2016 |
Flinn IW, Panayiotidis P, Afanasyev B, Janssens A, Grosicki S, Homenda W, Smolej L, Kuliczkowski K, Doubek M, Domnikova N, West SL, Chang CN, Barker AM, Gupta IV, Wright OJ, et al. A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. American Journal of Hematology. PMID 27222473 DOI: 10.1002/ajh.24430 |
0.364 |
|
| 2016 |
Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. The Lancet. Oncology. PMID 27049457 DOI: 10.1016/S1470-2045(15)00584-7 |
0.326 |
|
| 2016 |
Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, ... ... Flinn I, et al. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase 2 Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27040394 DOI: 10.1016/J.Bbmt.2016.03.018 |
0.342 |
|
| 2015 |
Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, Shustov AR, Thress KS, Mitchell P, Zheng F, Skolnik JM, Friedberg JW. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). European Journal of Cancer (Oxford, England : 1990). 54: 11-17. PMID 26707592 DOI: 10.1016/j.ejca.2015.10.005 |
0.319 |
|
| 2015 |
Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. The Lancet. Haematology. 2: e166-74. PMID 26687959 DOI: 10.1016/S2352-3026(15)00026-5 |
0.386 |
|
| 2015 |
O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. PMID 26472751 DOI: 10.1182/Blood-2015-03-630947 |
0.396 |
|
| 2015 |
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26056177 DOI: 10.1200/Jco.2014.58.7618 |
0.371 |
|
| 2015 |
Burke JM, van der Jagt RH, Flinn IW, Craig MD, Chen L, Morganroth J, Munteanu MC, MacDonald DA. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma. Cancer Chemotherapy and Pharmacology. PMID 26006703 DOI: 10.1007/s00280-015-2776-x |
0.354 |
|
| 2015 |
Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. The Lancet. Oncology. 16: 704-15. PMID 25925619 DOI: 10.1016/S1470-2045(15)70128-2 |
0.309 |
|
| 2015 |
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 125: 2915-22. PMID 25755291 DOI: 10.1182/blood-2014-09-585869 |
0.402 |
|
| 2015 |
Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 100: 670-6. PMID 25710456 DOI: 10.3324/haematol.2014.119735 |
0.397 |
|
| 2015 |
Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients. British Journal of Haematology. 168: 38-45. PMID 25146490 DOI: 10.1111/bjh.13099 |
0.431 |
|
| 2015 |
Ganjoo KN, de Vos S, Pohlman BL, Flinn IW, Forero-Torres A, Enas NH, Cronier DM, Dang NH, Foon KA, Carpenter SP, Slapak CA, Link BK, Smith MR, Mapara MY, Wooldridge JE. Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. Leukemia & Lymphoma. 56: 42-8. PMID 24717109 DOI: 10.3109/10428194.2014.911859 |
0.384 |
|
| 2015 |
Jurczak W, Gopal A, Kahl B, de Vos S, Wagner-Johnston N, Schuster S, Flinn I, Flowers C, Martin P, Viardot A, Blum K, Goy A, Davies A, Zinzani P, Dreyling M, et al. Mature Follow-up from a Phase-2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) Acta Haematologica Polonica. 46: 48-49. DOI: 10.1016/J.Achaem.2015.07.080 |
0.444 |
|
| 2014 |
Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 124: 3553-60. PMID 25301708 DOI: 10.1182/blood-2014-08-593269 |
0.336 |
|
| 2014 |
Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 167: 466-77. PMID 25130401 DOI: 10.1111/bjh.13061 |
0.38 |
|
| 2014 |
Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. The Lancet. Oncology. 15: 1019-26. PMID 25042202 DOI: 10.1016/S1470-2045(14)70311-0 |
0.345 |
|
| 2014 |
Hainsworth JD, Greco FA, Raefsky EL, Thompson DS, Lunin S, Reeves J, White L, Quinn R, DeBusk LM, Flinn IW. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 14: 277-83. PMID 24679633 DOI: 10.1016/j.clml.2014.02.010 |
0.305 |
|
| 2014 |
Schwartzberg L, Hermann R, Flinn I, Flora D, Hsi ED, Hamid O, Shi P, Lin BK, Myrand SP, Nguyen TS, Dreyling M. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma. British Journal of Haematology. 166: 91-7. PMID 24673609 DOI: 10.1111/bjh.12853 |
0.366 |
|
| 2014 |
Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 123: 3398-405. PMID 24615778 DOI: 10.1182/blood-2013-11-537555 |
0.415 |
|
| 2014 |
Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 123: 3390-7. PMID 24615777 DOI: 10.1182/blood-2013-11-535047 |
0.407 |
|
| 2014 |
Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 123: 3406-13. PMID 24615776 DOI: 10.1182/blood-2013-11-538546 |
0.398 |
|
| 2014 |
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. The New England Journal of Medicine. 370: 1008-18. PMID 24450858 DOI: 10.1056/NEJMoa1314583 |
0.315 |
|
| 2014 |
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine. 370: 997-1007. PMID 24450857 DOI: 10.1056/NEJMoa1315226 |
0.317 |
|
| 2014 |
Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 123: 1302-8. PMID 24381226 DOI: 10.1182/blood-2013-07-512137 |
0.354 |
|
| 2014 |
Furman RR, Vos Sd, Barrientos JC, Schreeder MT, Flinn IW, Sharman JP, Boyd TE, Fowler N, Leonard JP, Rai KR, Kim Y, Viggiano A, Jahn TM, Coutre SE. Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood. 124: 5653-5653. DOI: 10.1182/Blood.V124.21.5653.5653 |
0.467 |
|
| 2014 |
Barrientos JC, Coutre SE, Vos Sd, Wagner-Johnston ND, Flinn IW, Sharman JP, Schreeder MT, Boyd TE, Rai KR, Leonard JP, Kim Y, Viggiano A, Jahn TM, Furman RR. Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood. 124: 3343-3343. DOI: 10.1182/Blood.V124.21.3343.3343 |
0.494 |
|
| 2014 |
Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Hallek M, Coiffier B, O'Brien S, Tausch E, et al. Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors Blood. 124: 330-330. DOI: 10.1182/Blood.V124.21.330.330 |
0.328 |
|
| 2014 |
O'Brien S, Lamanna N, Kipps TJ, Flinn IW, Zelenetz AD, Burger JA, Holes LM, Cho Y, Dubowy RL, Coutre SE. Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Blood. 124: 1994-1994. DOI: 10.1182/Blood.V124.21.1994.1994 |
0.446 |
|
| 2014 |
Zelenetz AD, Lamanna N, Kipps TJ, Coutre SE, O'Brien S, Aiello M, Cho Y, Dubowy RL, Flinn IW. A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Blood. 124: 1986-1986. DOI: 10.1182/Blood.V124.21.1986.1986 |
0.486 |
|
| 2014 |
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak W, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy A, Davies A, Zinzani PL, Dreyling MH, et al. Mature Follow up from a Phase 2 Study of PI3K-Delta Inhibitor Idelalisib in Patients with Double (Rituximab and Alkylating agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) Blood. 124: 1708-1708. DOI: 10.1182/Blood.V124.21.1708.1708 |
0.466 |
|
| 2014 |
Ma AW, Atoyan R, Younes A, Flinn IW, Oki Y, Copeland A, Berdeja JG, Laliberte R, Viner J, Samson MES, Dellarocca S, Yi L, Borek M, Zifcak B, Xu G, et al. Abstract 1879: Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies Cancer Research. 74: 1879-1879. DOI: 10.1158/1538-7445.Am2014-1879 |
0.343 |
|
| 2014 |
Sharman J, Coutre S, Furman R, Cheson B, Pagel J, Hillmen P, Barrientos J, Zelenetz A, Kipps T, Flinn I, Ghia P, Hallek M, Coiffier B, O’Brien S, Stilgenbauer S. Pp-054 Efficacy Of Idelalisib In Cll Subpopulations Harboring Del(17P) And Other Adverse Prognostic Factors: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Leukemia Research. 38. DOI: 10.1016/S0145-2126(14)70108-0 |
0.306 |
|
| 2013 |
Shah NP, Talpaz M, Deininger MW, Mauro MJ, Flinn IW, Bixby D, Lustgarten S, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. British Journal of Haematology. 162: 548-52. PMID 23691988 DOI: 10.1111/Bjh.12382 |
0.359 |
|
| 2013 |
Palanca-Wessels MC, Salles GA, Czuczman MS, Assouline SE, Flinn IW, Sehn LH, Patel M, Sangha R, Tilly H, Advani R, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Lu D, et al. Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Blood. 122: 4400-4400. DOI: 10.1182/Blood.V122.21.4400.4400 |
0.422 |
|
| 2013 |
Younes A, Flinn IW, Oki Y, Copland A, Fattaey A, Lai C, Laliberte R, Voi M, Berdeja JG. A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma Blood. 122: 4363-4363. DOI: 10.1182/Blood.V122.21.4363.4363 |
0.447 |
|
| 2013 |
Vos SD, Leonard JP, Barrientos JC, Schreeder MT, Flinn IW, Sharman JP, Boyd T, Fowler N, Rai KR, Kim Y, Holes LM, Dansey R, Jahn TM, Coutre SE. A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia Blood. 122: 4180-4180. DOI: 10.1182/Blood.V122.21.4180.4180 |
0.443 |
|
| 2013 |
Kaplan D, Sun Z, Tallman MS, Flinn IW, Xiao W, Caimi PF, Kaye NM, Lazarus HM. Stratification Of CLL By ZAP-70 Expression: Analysis Of Samples From The ECOG-Led Intergroup Trial E2997 Blood. 122: 4116-4116. DOI: 10.1182/Blood.V122.21.4116.4116 |
0.343 |
|
| 2013 |
Douglas M, Allison K, Ted S, Allen K, Kahl BS, Horwitz SM, Flinn IW, Kelly P, Stern HM. Treatment With The Potent PI3K-δ,γ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma Blood. 122: 1633-1633. DOI: 10.1182/Blood.V122.21.1633.1633 |
0.411 |
|
| 2012 |
Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 26: 2197-203. PMID 22699418 DOI: 10.1038/leu.2012.134 |
0.338 |
|
| 2012 |
Pinilla-Ibarz J, Flinn I. The expanding options for front-line treatment in patients with newly diagnosed CML. Critical Reviews in Oncology/Hematology. 84: 287-99. PMID 22487423 DOI: 10.1016/j.critrevonc.2012.03.005 |
0.316 |
|
| 2012 |
Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leukemia & Lymphoma. 53: 2136-42. PMID 22475052 DOI: 10.3109/10428194.2012.681655 |
0.464 |
|
| 2012 |
Flinn IW, Cooper RS, Thompson DS, Waselenko JK, Reeves J, Wise RL, Hainsworth JD, Berdeja JG. Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute Blood. 120: 715-715. DOI: 10.1182/Blood.V120.21.715.715 |
0.451 |
|
| 2012 |
Palanca-Wessels MC, Flinn IW, Sehn LH, Patel M, Sangha R, Czuczman MS, Salles GA, Morschhauser F, Advani R, Press OW, Ho W, Kahn R, Lu D, Su Z, Chu Y, et al. A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Blood. 120: 56-56. DOI: 10.1182/Blood.V120.21.56.56 |
0.439 |
|
| 2012 |
Flinn IW, Mainwaring M, Peacock N, Shipley D, Arrowsmith E, Savona MR, Hainsworth JD, Berdeja JG. Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial. Blood. 120: 2748-2748. DOI: 10.1182/Blood.V120.21.2748.2748 |
0.527 |
|
| 2012 |
Flinn IW, Thompson DS, Boccia RV, Miletello G, Lipman A, Flora D, Cuevas D, Papish SW, Berdeja JG. Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute Blood. 120: 1624-1624. DOI: 10.1182/Blood.V120.21.1624.1624 |
0.455 |
|
| 2012 |
Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim D, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up Leukemia. 26: 2302-2302. DOI: 10.1038/Leu.2012.175 |
0.346 |
|
| 2011 |
Leonard J, Reeves J, Ferhanoglu B, Doner KT, Eom H, Flinn IW, Raposo J, Chowhan NM, Suh C, Noga S, Tumyan G, Aung S, Hajdenberg J, Ulrich BK, Pendergrass KB, et al. PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS226. PMID 28023541 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps226 |
0.421 |
|
| 2011 |
Niesvizky R, Flinn IW, Rifkin RM, Gabrail N, Charu V, Gaffar Y, Neuwirth R, Corzo D, Reeves J. Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8072. PMID 28023490 DOI: 10.1200/Jco.2011.29.15_Suppl.8072 |
0.386 |
|
| 2011 |
Flinn IW, Schreeder MT, Coutre SE, Leonard J, Wagner-Johnston ND, De Vos S, Boccia RV, Holes L, Peterman S, Miller LL, Yu AS. A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3064. PMID 28022568 DOI: 10.1200/Jco.2011.29.15_Suppl.3064 |
0.451 |
|
| 2011 |
Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner-Johnston ND, Flinn IW, Kahl BS, Spurgeon SE, Lannutti BJ, Hsu HK, Ulrich R, Peterman S, Holes L, Miller LL, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6631. PMID 28020216 DOI: 10.1200/Jco.2011.29.15_Suppl.6631 |
0.351 |
|
| 2011 |
Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, O'Brien SM. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6508. PMID 28020000 DOI: 10.1200/Jco.2011.29.15_Suppl.6508 |
0.401 |
|
| 2011 |
Talpaz M, Shah NP, Deininger MW, Mauro MJ, Flinn IW, Lustgarten S, Lindmark W, Gozgit JM, Clackson T, Turner CD, Haluska FG, Kantarjian H, Cortes JE. Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6518. PMID 28019981 DOI: 10.1200/Jco.2011.29.15_Suppl.6518 |
0.384 |
|
| 2011 |
Gladstone DE, Bolaños-Meade J, Huff CA, Zahurak M, Flinn I, Borrello I, Luznik L, Fuchs E, Kasamon Y, Matsui W, Powell J, Levitsky H, Brodsky RA, Ambinder R, Jones RJ, et al. High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leukemia & Lymphoma. 52: 2076-81. PMID 21756035 DOI: 10.3109/10428194.2011.594191 |
0.481 |
|
| 2011 |
Flinn IW, Harwin WN, Ward P, Doss HH, Papish SW, Hainsworth JD, Berdeja JG, Byrd JC. Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Blood. 120: 719-719. DOI: 10.1182/Blood.V118.21.3912.3912 |
0.458 |
|
| 2011 |
Berdeja JG, Couriel DR, Murphy P, Boccia RV, Priego V, Hainsworth JD, Macias-Pérez IM, Flinn IW. A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis Blood. 118: 2943-2943. DOI: 10.1182/Blood.V118.21.2943.2943 |
0.444 |
|
| 2011 |
Pagel JM, Spurgeon S, Awan F, Blum KA, Lanasa MC, Flinn IW, Stromatt S, Byrd JC, Gopal AK. Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients Blood. 118: 1636-1636. DOI: 10.1182/Blood.V118.21.1636.1636 |
0.512 |
|
| 2010 |
Hainsworth JD, Flinn IW, Spigel DR, Clark BL, Griner PL, Vazquez ER, Doss HH, Shipley D, Franco LA, Burris HA, Greco FA. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clinical Lymphoma, Myeloma & Leukemia. 10: 44-50. PMID 20223728 DOI: 10.3816/CLML.2010.n.004 |
0.366 |
|
| 2010 |
Kasamon YL, Jones RJ, Brodsky RA, Fuchs EJ, Matsui W, Luznik L, Powell JD, Blackford AL, Goodrich A, Gocke CD, Abrams RA, Ambinder RF, Flinn IW. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 1203-10. PMID 19880437 DOI: 10.1093/Annonc/Mdp484 |
0.339 |
|
| 2010 |
Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 115: 489-95. PMID 19843887 DOI: 10.1182/Blood-2009-08-237727 |
0.512 |
|
| 2010 |
Schwartzberg L, Hermann RC, Flinn IW, Flora DB, Song J, Hamid O, Lin BK, Dreyling MH. Enzastaurin in patients with follicular lymphoma: Results of a phase II study. Journal of Clinical Oncology. 28: 8040-8040. DOI: 10.1200/Jco.2010.28.15_Suppl.8040 |
0.385 |
|
| 2010 |
Furman RR, Byrd JC, Flinn IW, Coutre SE, Benson DM, Brown JR, Kahl BS, Wagner-Johnston ND, Giese NA, Yu AS. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. Journal of Clinical Oncology. 28: 3032-3032. DOI: 10.1200/Jco.2010.28.15_Suppl.3032 |
0.442 |
|
| 2009 |
Andritsos L, Furman R, Flinn IW, Foreno-Torres A, Flynn JM, Stromatt SC, Byrd JC. A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3017. PMID 27962057 DOI: 10.1200/Jco.2009.27.15_Suppl.3017 |
0.368 |
|
| 2009 |
Flinn IW, Byrd JC, Furman RR, Brown JR, Lin TS, Bello C, Giese NA, Yu AS. Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3543. PMID 27961357 DOI: 10.1200/Jco.2009.27.15_Suppl.3543 |
0.401 |
|
| 2009 |
Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leukemia & Lymphoma. 50: 1958-63. PMID 19860603 DOI: 10.3109/10428190903186486 |
0.337 |
|
| 2008 |
Swinnen LJ, Flinn IW, Kahl BS, Frey E, Rogers K, Jung M, Jacene H, Wahl RL. Phase I trial of yttrium 90 ibritumomab tiuxetan ((90)Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8565. PMID 27951111 DOI: 10.1200/Jco.2008.26.15_Suppl.8565 |
0.445 |
|
| 2008 |
Byrd JC, Castro JE, Flinn IW, Forero-Torres A, Kipps TJ, Heerema NA, Lin TS, Mu H, Tangri S, O' Brien S. Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7003. PMID 27949958 DOI: 10.1200/Jco.2008.26.15_Suppl.7003 |
0.401 |
|
| 2007 |
Molina A, Krishnan A, Fung H, Flinn IW, Inwards D, Winter JN, Nademanee A. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan. Current Stem Cell Research & Therapy. 2: 239-48. PMID 18220907 DOI: 10.2174/157488807781696230 |
0.369 |
|
| 2007 |
Bolaños-Meade J, Garrett-Mayer E, Luznik L, Anders V, Webb J, Fuchs EJ, Huff CA, Matsui W, Borrello IM, Brodsky R, Kasamon YL, Swinnen LJ, Flinn IW, Ambinder RF, Jones RJ, et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 1185-91. PMID 17889355 DOI: 10.1016/J.Bbmt.2007.06.011 |
0.396 |
|
| 2007 |
Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 4448-55. PMID 17671129 DOI: 10.1158/1078-0432.Ccr-06-1463 |
0.432 |
|
| 2007 |
Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins D, Newton S, Flinn IW. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2392-9. PMID 17438098 DOI: 10.1158/1078-0432.CCR-06-1860 |
0.32 |
|
| 2007 |
Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif M, Macklis R, Vo K, Wiseman GA. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 109: 1804-10. PMID 17380530 DOI: 10.1002/Cncr.22617 |
0.455 |
|
| 2007 |
Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 793-8. PMID 17283364 DOI: 10.1200/Jco.2006.08.0762 |
0.467 |
|
| 2007 |
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 799-804. PMID 17283363 DOI: 10.1200/Jco.2006.08.3089 |
0.462 |
|
| 2007 |
Kasamon YL, Flinn IW. Management of symptomatic, untreated chronic lymphocytic leukemia. Blood Reviews. 21: 143-56. PMID 17097783 DOI: 10.1016/j.blre.2006.10.001 |
0.305 |
|
| 2006 |
Aksentijevich I, Jones RJ, Ambinder RF, Garrett-Mayer E, Flinn IW. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 965-72. PMID 16920563 DOI: 10.1016/J.Bbmt.2006.05.018 |
0.455 |
|
| 2006 |
Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer. 107: 916-24. PMID 16832816 DOI: 10.1002/Cncr.22097 |
0.512 |
|
| 2006 |
Flinn IW, Berdeja JG. Blood and bone marrow transplantation for patients with Hodgkin's and non-Hodgkin's lymphoma. Cancer Treatment and Research. 131: 251-81. PMID 16704172 DOI: 10.1007/978-0-387-29346-2_8 |
0.475 |
|
| 2006 |
Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leukemia & Lymphoma. 47: 629-36. PMID 16690521 DOI: 10.1080/10428190500376076 |
0.51 |
|
| 2006 |
Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 414-21. PMID 16545725 DOI: 10.1016/J.Bbmt.2005.11.520 |
0.41 |
|
| 2006 |
Willis CR, Goodrich A, Park K, Waselenko JK, Lucas M, Reese A, Diehl LF, Grever MR, Byrd JC, Flinn IW. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Annals of Hematology. 85: 301-7. PMID 16518606 DOI: 10.1007/S00277-005-0025-9 |
0.525 |
|
| 2006 |
Kasamon YL, Wahl R, Ziessman H, Garrett-Mayer E, Jones RJ, Ambinder RF, Flinn IW, Swinnen LJ. Phase II study of preemptive high dose chemotherapy and autologous stem cell transplantation for lymphoma based on early FDG-PET scanning Journal of Clinical Oncology. 24: 7561-7561. DOI: 10.1200/Jco.2006.24.18_Suppl.7561 |
0.363 |
|
| 2006 |
O'Brien S, Byrd JC, Kipps TJ, Forero-Torres A, Flinn IW, Wynne DI, Molina A. Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL) Journal of Clinical Oncology. 24: 6597-6597. DOI: 10.1200/Jco.2006.24.18_Suppl.6597 |
0.437 |
|
| 2006 |
Grever MR, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Appelbaum FR, Larson RA, Tallman MS, Gribben JG, Byrd JC. Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy Journal of Clinical Oncology. 24: 6521-6521. DOI: 10.1200/Jco.2006.24.18_Suppl.6521 |
0.403 |
|
| 2006 |
Byrd JC, Castro J, O’Brien S, Flinn IW, Forero-Torres A, Kipps TJ, Heerema NA, Lin T, Kheoh T, Wynnem D, Molina A. Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results. Blood. 108: 32-32. DOI: 10.1182/Blood.V108.11.32.32 |
0.448 |
|
| 2006 |
Byrd JC, Flinn IW, Khan KD, Kipps TJ, Aukerman L, Fox J, Girish S, Guzy S, Bilic S, Solinger A, Dort S, Wang Y, Hurst D, O’Brien S. Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia. Blood. 108: 2837-2837. DOI: 10.1182/Blood.V108.11.2837.2837 |
0.446 |
|
| 2006 |
Rassenti LZ, Neuberg DS, Huynh L, Wierda WG, Gribben JG, Brown JR, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Relative Value of CD38 and ZAP-70 Versus Immunoglobulin Mutation Status in Predicting Early Disease Progression in Chronic Lymphocytic Leukemia. Blood. 108: 2778-2778. DOI: 10.1182/Blood.V108.11.2778.2778 |
0.374 |
|
| 2006 |
Ghia EM, Rassenti LZ, Widhopf GF, Neuberg DS, Keating MJ, Wierda WG, Gribben JG, Brown JR, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Study of VH3-21 in a Large Cohort of Chronic Lymphocytic Leukemia Patients Reveals Evidence for Antigen Selection and Confirms Its Predictive Value for Early Disease Progression. Blood. 108: 2774-2774. DOI: 10.1182/Blood.V108.11.2774.2774 |
0.4 |
|
| 2006 |
Swinnen LJ, Jones RJ, Jung M, Flinn IW. Phase II Study of High Dose Outpatient Cyclophosphamide and Rituximab, without Stem Cell Support, for Low Grade and Mantle Cell Lymphoma. Blood. 108: 2741-2741. DOI: 10.1182/Blood.V108.11.2741.2741 |
0.522 |
|
| 2006 |
Furman RR, Bartlett NL, Wong AF, McCulloch LM, Lam GN, Rosenthal T, Flinn I, Leonard JP. Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas. Blood. 108: 2429-2429. DOI: 10.1182/Blood.V108.11.2429.2429 |
0.385 |
|
| 2005 |
Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8413-7. PMID 16322303 DOI: 10.1158/1078-0432.Ccr-05-1612 |
0.417 |
|
| 2005 |
Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leukemia Research. 29: 1253-7. PMID 15916806 DOI: 10.1016/J.Leukres.2005.03.010 |
0.361 |
|
| 2005 |
Lin TS, Flinn IW, Lucas MS, Porcu P, Sickler J, Moran ME, Lucas DM, Heerema NA, Grever MR, Byrd JC. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia. 19: 1207-10. PMID 15858611 DOI: 10.1038/Sj.Leu.2403782 |
0.473 |
|
| 2005 |
Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, Morrison C, Smith BD, Flinn IW. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 93-100. PMID 15682069 DOI: 10.1016/J.Bbmt.2004.09.009 |
0.479 |
|
| 2005 |
Kasamon YL, Jones RJ, Diehl LF, Nayer H, Borowitz MJ, Garrett-Mayer E, Ambinder RF, Abrams RA, Zhang Z, Flinn IW. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 39-46. PMID 15625543 DOI: 10.1016/J.Bbmt.2004.09.007 |
0.421 |
|
| 2005 |
Schilder RJ, Emmanouilides C, Vo K, Witzig TE, Flinn I, Darif M, Gordon L, Molina A. Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL Journal of Clinical Oncology. 23: 6562-6562. DOI: 10.1200/Jco.2005.23.16_Suppl.6562 |
0.371 |
|
| 2005 |
Fukuda T, Neuberg DS, Huynh L, Rassenti LZ, Toy TL, Rai KR, Keating MJ, Gribben JG, Flinn IW, Byrd JC, Kay NE, Kipps TJ. Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia. Blood. 106: 2943-2943. DOI: 10.1182/Blood.V106.11.2943.2943 |
0.366 |
|
| 2004 |
Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 163-83. PMID 15561682 DOI: 10.1016/S0305-7372(96)90013-4 |
0.437 |
|
| 2004 |
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. The New England Journal of Medicine. 351: 893-901. PMID 15329427 DOI: 10.1056/Nejmoa040857 |
0.32 |
|
| 2004 |
Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5432-8. PMID 15328181 DOI: 10.1158/1078-0432.Ccr-04-0540 |
0.473 |
|
| 2004 |
Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 103: 3278-81. PMID 14726385 DOI: 10.1182/Blood-2003-10-3729 |
0.408 |
|
| 2004 |
Kitada S, Reed JC, Lucas DM, Neuberg DS, Gribben JG, Dewald GW, Flinn IW, Tallman MS, Byrd JC, Grever MR. Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment. Blood. 104: 956-956. DOI: 10.1182/Blood.V104.11.956.956 |
0.387 |
|
| 2004 |
Lucas DM, Dewald GW, Neuberg DS, Byrd JC, Lozanski G, Harbison J, Cunningham KD, Flinn IW, Tallman MS, Grever MR. Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used. Blood. 104: 949-949. DOI: 10.1182/Blood.V104.11.949.949 |
0.321 |
|
| 2004 |
Kasamon YL, Jones RJ, Diehl LF, Nayer H, Borowitz MJ, Garrett-Mayer E, Ambinder RF, Abrams RA, Zhang Z, Flinn IW. Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma. Blood. 104: 901-901. DOI: 10.1182/Blood.V104.11.901.901 |
0.399 |
|
| 2004 |
Flinn IW, Kahl BS, Frey E, Bianco JA, Hammes RJ, Billing LS, Swinnen LJ, Sgouros G, Wahl RL. Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL). Blood. 104: 897-897. DOI: 10.1182/Blood.V104.11.897.897 |
0.494 |
|
| 2004 |
Faderl S, Rai KR, Gribben J, Flinn I, Byrd JC, McConkey D, Schenkein D, Esseltine D, Browning ML, Keating MJ. Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL. Blood. 104: 4841-4841. DOI: 10.1182/Blood.V104.11.4841.4841 |
0.461 |
|
| 2004 |
Woodworth J, Leigh BR, O’Brien S, Flinn I, Kipps TJ, Weiss MA, Rai K, Thall A, Wynne D, Byrd JC. Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia. Blood. 104: 4831-4831. DOI: 10.1182/Blood.V104.11.4831.4831 |
0.393 |
|
| 2004 |
Bartlett NL, Gribben JG, Boccia RV, Milder MS, Aboulafia DM, Castro J, Flinn I, Hayes-Lattin B, Kaplan L, Lin T, Lucas JB, Maloney DG, McLaughlin P, McSweeney PA, Mohrbacher A, et al. A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL). Blood. 104: 4640-4640. DOI: 10.1182/Blood.V104.11.4640.4640 |
0.366 |
|
| 2004 |
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Flinn IW, Tallman MS, Gribben JG, Byrd JC. Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997. Blood. 104: 3487-3487. DOI: 10.1182/Blood.V104.11.3487.3487 |
0.327 |
|
| 2004 |
Rassenti LZ, Neuberg DS, Keating MJ, Gribben JG, Flinn IW, Rai KR, Byrd JC, Kay NE, Kipps TJ. CD38 Compared with ZAP-70 or Immmunoglobulin Mutation Status as Predictor of Disease Progression in Chronic Lymphocytic Leukemia. Blood. 104: 2805-2805. DOI: 10.1182/Blood.V104.11.2805.2805 |
0.344 |
|
| 2004 |
Motiwala T, Ghoshal K, Majumder S, Kutay H, Neuberg DS, Kitada S, Reed JC, Dewald GW, Flinn IW, Tallman MA, Liu T, Plass C, Lucas DM, Byrd JC, Jacob ST, et al. Methylation of the Tumor Suppressor Gene PTPRO (Receptor-Type Protein Tyrosine Phosphatase) Is Associated with Expression of Important Apoptosis-Related Proteins in Chronic Lymphocytic Leukemia (CLL). Blood. 104: 2804-2804. DOI: 10.1182/Blood.V104.11.2804.2804 |
0.351 |
|
| 2004 |
Schilder RJ, Witzig TE, Flinn I, Gordon LI, Emmanouilides C, Wang H, Vo K, Molina A. Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL). Blood. 104: 2629-2629. DOI: 10.1182/Blood.V104.11.2629.2629 |
0.469 |
|
| 2004 |
Byrd JC, O’Brien S, Flinn I, Kipps TJ, Weiss MA, Rai K, Lin TS, Reid J, Wynne D, Leigh BR. Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia. Blood. 104: 2503-2503. DOI: 10.1182/Blood.V104.11.2503.2503 |
0.464 |
|
| 2003 |
Malek SN, Flinn IW. Incorporating monoclonal antibodies in blood and marrow transplantation. Seminars in Oncology. 30: 520-30. PMID 12939721 DOI: 10.1016/S0093-7754(03)00238-0 |
0.368 |
|
| 2003 |
Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1466-71. PMID 12697868 DOI: 10.1200/Jco.2003.06.012 |
0.391 |
|
| 2003 |
Aksentijevich I, Flinn IW. Chronic lymphocytic leukemia: advances in biology and therapeutics. Current Opinion in Oncology. 15: 16-22. PMID 12490757 DOI: 10.1097/00001622-200301000-00003 |
0.432 |
|
| 2003 |
Flinn IW, Diehl L, Garrett E, Carter-Brookins D, Goodrich A, Loper K, Jones RJ, Ambinder RF. 24 In vivo purging and post transplant immunotherapy with rituximab produces durable remissions in patients with low grade and mantle cell lymphoma Biology of Blood and Marrow Transplantation. 9: 70-71. DOI: 10.1016/S1083-8791(03)80025-3 |
0.435 |
|
| 2002 |
Gordon LI, Witzig TE, Wiseman GA, Flinn IW, Spies SS, Silverman DH, Emmanuolides C, Cripe L, Saleh M, Czuczman MS, Olejnik T, White CA, Grillo-López AJ. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Seminars in Oncology. 29: 87-92. PMID 28140097 DOI: 10.1053/Sonc.2002.30148 |
0.397 |
|
| 2002 |
Aksentijevich I, Flinn I. Chemotherapy and bone marrow reserve: lessons learned from autologous stem cell transplantation. Cancer Biotherapy and Radiopharmaceuticals. 17: 399-403. PMID 12396704 DOI: 10.1089/108497802760363196 |
0.351 |
|
| 2002 |
Flinn IW. Lymphoma therapy: the challenges ahead. Current Opinion in Oncology. 14: 473-4. PMID 12192264 DOI: 10.1097/00001622-200209000-00001 |
0.315 |
|
| 2002 |
Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 3262-9. PMID 12149300 DOI: 10.1200/Jco.2002.11.017 |
0.426 |
|
| 2002 |
Smith BD, Jones RJ, Lee SM, Piantadosi S, Vala MS, Fuller D, Gore SD, Noga SJ, O'Donnell PV, Braine H, Vogelsang GB, Fuchs EJ, Flinn IW, Brodsky RA, Ambinder RF, et al. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. British Journal of Haematology. 117: 907-13. PMID 12060130 DOI: 10.1046/J.1365-2141.2002.03530.X |
0.384 |
|
| 2002 |
Aksentijevich I, Flinn IW. Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Cancer Control : Journal of the Moffitt Cancer Center. 9: 99-105. PMID 12008655 DOI: 10.1177/107327480200900202 |
0.373 |
|
| 2002 |
Keating MJ, Flinn I, Jain V, Binet J, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 99: 3554-3561. PMID 11986207 DOI: 10.1182/Blood.V99.10.3554 |
0.467 |
|
| 2002 |
Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 99: 1038-43. PMID 11807010 DOI: 10.1182/Blood.V99.3.1038 |
0.433 |
|
| 2001 |
Noga SJ, Vogelsang GB, Miller SC, Meusel S, Loper K, Case R, Myers B, Rogers L, Flinn I, Borowitz M, O'Donnell P. Using point-of-care CD34 enumeration to optimize PBSC collection conditions. Cytotherapy. 3: 11-8. PMID 12028839 DOI: 10.1080/146532401753156368 |
0.311 |
|
| 2001 |
Berdeja JG, Jones RJ, Zahurak ML, Piantadosi S, Abrams RA, Borowitz MJ, Vogelsang GB, Noga SJ, Ambinder RF, Flinn IW. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 7: 561-7. PMID 11760088 DOI: 10.1016/S1083-8791(01)70016-X |
0.44 |
|
| 2001 |
Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak ML, Fuller D, Miller CB, Noga SJ, Fuchs E, Flinn IW, O'Donnell P, Seifter EJ, Mann RB, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 4314-21. PMID 11731514 DOI: 10.1200/Jco.2001.19.23.4314 |
0.35 |
|
| 2001 |
Waselenko JK, Shinn CA, Willis CR, Flinn IW, Grever MR, Byrd JC. Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells. Leukemia & Lymphoma. 42: 1049-53. PMID 11697622 DOI: 10.3109/10428190109097725 |
0.405 |
|
| 2001 |
Berdeja JG, Flinn IW. New approaches to blood and marrow transplantation for patients with low-grade lymphomas Current Opinion in Oncology. 13: 335-341. PMID 11555709 DOI: 10.1097/00001622-200109000-00004 |
0.347 |
|
| 2001 |
Byrd JC, Shinn C, Willis CR, Flinn IW, Lehman T, Sausville E, Lucas D, Grever MR. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism Experimental Hematology. 29: 703-708. PMID 11378265 DOI: 10.1016/S0301-472X(01)00649-X |
0.401 |
|
| 2001 |
Waselenko JK, Grever MR, Shinn CA, Flinn IW, Byrd JC. Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia. Leukemia Research. 25: 435-40. PMID 11337014 DOI: 10.1016/S0145-2126(00)00106-5 |
0.412 |
|
| 2001 |
Flinn IW, Lazarus HM. Monoclonal antibodies and autologous stem cell transplantation for lymphoma Bone Marrow Transplantation. 27: 565-569. PMID 11319583 DOI: 10.1038/Sj.Bmt.1702857 |
0.344 |
|
| 2001 |
Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 2153-64. PMID 11304767 DOI: 10.1200/Jco.2001.19.8.2153 |
0.43 |
|
| 2001 |
Noga SJ, Vogelsang GB, Loper KA, Meusel S, Flinn I, O'Donnell PV. Using real time peripheral blood (PB) CD34 measurement in conjunction with a standardized priming regimen identifies differences in mobilization kinetics among patients with hematologic malignancies (HM) Transfusion and Apheresis Science. 24: 177-178. DOI: 10.1016/S1473-0502(01)00030-1 |
0.35 |
|
| 2000 |
Flinn IW, O'Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S, Marcellus D, Borowitz M, Jones R, Ambinder RF. Immunotherapy with Rituximab during Peripheral Blood Stem Cell Transplantation for Non-Hodgkin's Lymphoma Biology of Blood and Marrow Transplantation. 6: 628-632. PMID 11128813 DOI: 10.1016/S1083-8791(00)70028-0 |
0.479 |
|
| 2000 |
Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, Caligiuri MA, Ambinder RF. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response Blood. 96: 4055-4063. PMID 11110673 DOI: 10.1182/Blood.V96.13.4055.H8004055_4055_4063 |
0.379 |
|
| 2000 |
Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 96: 2981-6. PMID 11049974 DOI: 10.1182/Blood.V96.9.2981.H8002981_2981_2986 |
0.438 |
|
| 2000 |
Flinn IW, Goodman SN, Post L, Jamison J, Miller CB, Gore S, Diehl L, Willis C, Ambinder RF, Byrd JC. A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL Annals of Oncology. 11: 691-695. PMID 10942057 DOI: 10.1023/A:1008361914894 |
0.437 |
|
| 2000 |
Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Piantadosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies Blood. 96: 71-75. PMID 10891432 DOI: 10.1182/Blood.V96.1.71.013K21_71_75 |
0.501 |
|
| 2000 |
Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF. Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens Blood. 95: 241-248. DOI: 10.1182/Blood.V95.1.241 |
0.328 |
|
| 2000 |
Noga SJ, O'Donnell PV, Flinn I, Loper KA, Meusal S, Vogelsang GB. Do mobilization kinetics differ among hematological malignancies (Hm) When priming and collection methods are optimized Experimental Hematology. 28: 94. DOI: 10.1016/S0301-472X(00)00380-5 |
0.372 |
|
| 1999 |
Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells Blood. 94: 1401-1408. PMID 10438728 DOI: 10.1182/Blood.V94.4.1401.416K30_1401_1408 |
0.401 |
|
| 1998 |
O'Donnell PV, Jones RJ, Vogelsang GB, Seber A, Ambinder RF, Flinn I, Miller C, Marcellus DC, Griffin C, Abrams R, Braine HG, Grever M, Hess AD, Piantadosi S, Noga SJ. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. Bone Marrow Transplantation. 22: 947-955. PMID 9849691 DOI: 10.1038/Sj.Bmt.1701476 |
0.44 |
|
| 1998 |
Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 Blood. 92: 3804-3816. PMID 9808574 DOI: 10.1182/Blood.V92.10.3804.422K36_3804_3816 |
0.372 |
|
| 1998 |
Morrison C, Shah S, Flinn IW. Leptomeningeal involvement in chronic lymphocytic leukemia Cancer Practice. 6: 223-228. PMID 9767335 DOI: 10.1046/J.1523-5394.1998.006004223.X |
0.368 |
|
| 1996 |
Flinn IW, Ambinder RF. AIDS primary central nervous system lymphoma Current Opinion in Oncology. 8: 373-376. PMID 9026061 DOI: 10.1097/00001622-199609000-00007 |
0.368 |
|
| Show low-probability matches. |